176 related articles for article (PubMed ID: 35069595)
1. Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients.
Del Bianco P; Pinton L; Magri S; Canè S; Masetto E; Basso D; Padovan M; Volpin F; d'Avella D; Lombardi G; Zagonel V; Bronte V; Della Puppa A; Mandruzzato S
Front Immunol; 2021; 12():809826. PubMed ID: 35069595
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
Raychaudhuri B; Rayman P; Ireland J; Ko J; Rini B; Borden EC; Garcia J; Vogelbaum MA; Finke J
Neuro Oncol; 2011 Jun; 13(6):591-9. PubMed ID: 21636707
[TBL] [Abstract][Full Text] [Related]
3. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
[TBL] [Abstract][Full Text] [Related]
4. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
8. [Changed percentage of myeloid-derived suppressor cells in the peripheral blood of prostate cancer patients and its clinical implication].
Zhou QZ; Liu CD; Yang JK; Guo WB; Zhou JH; Bian J
Zhonghua Nan Ke Xue; 2016 Nov; 22(11):963-967. PubMed ID: 29281201
[TBL] [Abstract][Full Text] [Related]
9. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V; Di Guardo L; Lalli L; Giardiello D; Cova A; Squarcina P; Frati P; Di Giacomo AM; Pilla L; Tazzari M; Camisaschi C; Arienti F; Castelli C; Rodolfo M; Beretta V; Di Nicola M; Maio M; Del Vecchio M; de Braud F; Mariani L; Rivoltini L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589521
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
11. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
[TBL] [Abstract][Full Text] [Related]
12. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis.
Liu YF; Zhuang KH; Chen B; Li PW; Zhou X; Jiang H; Zhong LM; Liu FB
Arthritis Res Ther; 2018 Aug; 20(1):168. PubMed ID: 30075733
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
14. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
Pinton L; Masetto E; Vettore M; Solito S; Magri S; D'Andolfi M; Del Bianco P; Lollo G; Benoit JP; Okada H; Diaz A; Della Puppa A; Mandruzzato S
J Immunother Cancer; 2019 Feb; 7(1):58. PubMed ID: 30813960
[TBL] [Abstract][Full Text] [Related]
15. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
17. Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission.
Tyrinova TV; Batorov EV; Aristova TA; Ushakova GY; Sizikova SA; Denisova VV; Ostanin AA; Chernykh ER
Bull Exp Biol Med; 2022 Nov; 174(1):71-75. PubMed ID: 36437327
[TBL] [Abstract][Full Text] [Related]
18. Myeloid cells in circulation and tumor microenvironment of breast cancer patients.
Toor SM; Syed Khaja AS; El Salhat H; Faour I; Kanbar J; Quadri AA; Albashir M; Elkord E
Cancer Immunol Immunother; 2017 Jun; 66(6):753-764. PubMed ID: 28283696
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
[TBL] [Abstract][Full Text] [Related]
20. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
